drugset / Trial / NCT04976283
Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver
RandomizedParallel-groupOpen-labelTreatment
Summary
This randomized clinical trial aims to compare the effect of the pioglitazone and SGLT2 inhibitor combination on liver fat mass, as compared to either drug used alone, with or without background medical therapy of metformin and/or DDP4 inhibitors.
Timeline
- Start
- 2021-09-15
- Primary completion
- 2023-05-15
- Completion
- 2023-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Empagliflozin | Small molecule | 25 mg | Oral |
| Comparator | Pioglitazone | Small molecule | 45 mg | Oral |